Replies to post #339055 on Avid Bioservices Inc (CDMO)

[flyingfurter]

We should've seen $28 was the targeted minimum when the financing was announced, those who bought the deal at 1.5% are really looking to buy additional shares at that price. The question is to what premium, 2X ($56) or 3X ($84)? Yes, that sounds completely crazy but if anyone had told you we'd be here on July 1 we would've called them crazy. The SP is what it is and it's doing what they want, glad to have stuck around for the ride.

Careful around this rocket, lot's of ways to get burned!

CDMO strong like bull and about to run through a brick wall!

[north40000]

Just some thoughts on the matters you mention:

https://investor.anipharmaceuticals.com/governance/board-of-directors/default.aspx

"Patrick D. Walsh Chairman of the Board
Mr. Walsh has served as a director since May 2018 and has been Chairman of the Board since June 2020. He also served as interim Chief Executive Officer of ANI from May 2020 to September 2020. In March 2021, Mr. Walsh was appointed as Chairman and Chief Executive Officer of Alcami, a global pharmaceutical contract development and manufacturing organization. Mr. Walsh co-founded TriPharm Services, an injectable manufacturing business which was acquired by Alcami, and served as its Chief Executive Officer from May 2019 to April 2020. From 2015 to February 2019, Mr. Walsh was the Chief Executive Officer of Avista Pharma, a private equity-backed global provider of contract manufacturing, development and analytical testing services that was acquired by Cambrex. Mr. Walsh’s earlier career includes serving as Chief Executive Officer of AAIPharma Services Corporation in Wilmington, North Carolina, a global provider of contract manufacturing services that was acquired in 2014, as Chief Executive Officer of Kadmus Pharma, which was acquired by Organon Pharma, and also serving as President and Chief Operating Officer and board member of publicly-traded Gensia-Sicor, which was acquired by Teva.

Mr. Walsh currently serves as an independent board of director of Avid Bioservices (NASDAQ: CDMO), an independent director of Landec Corp (NASDAQ: LNDC), and an independent director of Industria Chemica Emiliano (I.C.E), a private-equity backed specialty chemical company based in Milan, Italy. Mr. Walsh is an Operating Partner (part-time) at healthcare private equity firm Ampersand Capital and is also Chairman and founder of Diligence Group LLC based in Durham, North Carolina."

[tech0200]

What other options does Green have but to finish the expansion under way. I would say none.